Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection
This study has been completed.
Study NCT00034359   Information provided by Achillion Pharmaceuticals

First Received on April 26, 2002.   Last Updated on July 20, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis B, Chronic
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
ACH-126, 443 (beta-L-Fd4C)
Additional drug interventions recognized in this trial
Antiviral Agents
More general drug interventions related to this trial
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Achillion Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services